Amivantamab-Lazertinib Ups Survival in EGFR-Mutated Advanced Lung Cancer
By Elana Gotkine HealthDay Reporter
MONDAY, July 1, 2024 -- For patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC), amivantamab-lazertinib yields improved progression-free survival compared with osimertinib as first-line treatment, according to a study published online June 26 in the New England Journal of Medicine.
Byoung C. Cho, M.D., Ph.D., from the Yonsei Cancer Center in Seoul, South Korea, and colleagues conducted a phase 3 trial involving patients with previously untreated EGFR-mutated, locally advanced or metastatic NSCLC randomly allocated to receive amivantamab-lazertinib (open-label), osimertinib (blinded), or lazertinib (blinded) in a 2:2:1 ratio (429, 429, and 216 patients, respectively).
The researchers found that the median progression-free survival was significantly longer in the amivantamab-lazertinib group than in the osimertinib group (23.7 versus 16.6 months; hazard ratio for disease progression or death, 0.70). An objective response was observed in 86 and 85 percent of patients in the amivantamab-lazertinib and osimertinib groups, respectively; among patients with a confirmed response, the median response duration was 25.8 and 16.8 months, respectively. The hazard ratio for death did not differ significantly in a planned interim overall survival analysis of amivantamab-lazertinib versus osimertinib. EGFR-related toxic effects were the predominant adverse events. The incidence of discontinuation of all agents due to treatment-related adverse events was 10 and 3 percent with amivantamab-lazertinib and osimertinib, respectively.
"We found that progression-free survival was significantly improved with amivantamab-lazertinib as compared with osimertinib as first-line treatment for EGFR-mutated advanced NSCLC," the authors write.
Several authors disclosed ties to biopharmaceutical companies, including Janssen, which manufactures amivantamab and lazertinib and funded the study.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted July 2024
Read this next
Durable Disease Control Possible After Stopping Immune Checkpoint Inhibitors in NSCLC
TUESDAY, April 22, 2025 -- Prolonged disease control can be maintained for patients with advanced non-small cell lung cancer (NSCLC) who discontinue immune checkpoint inhibitors...
Breast, Colorectal Cancer Screening Higher Than Lung Cancer Screening
TUESDAY, April 15, 2025 -- Among individuals eligible for lung cancer screening (LCS), use of breast cancer screening (BCS) and colorectal cancer screening (CCS) is much higher...
More Than 3.8 Million U.S. Lung Cancer Deaths Averted During 1970 to 2022
TUESDAY, April 1, 2025 -- More than 3.8 million U.S. lung cancer deaths were averted during 1970 to 2022, and more than 76 million person-years of life were gained, according to a...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.